421 related articles for article (PubMed ID: 33755878)
1. A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome.
Almalki WH
Mol Cell Biochem; 2021 Aug; 476(8):2943-2949. PubMed ID: 33755878
[TBL] [Abstract][Full Text] [Related]
2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
3. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
4. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
[TBL] [Abstract][Full Text] [Related]
5. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource.
Azziz R; Kintziger K; Li R; Laven J; Morin-Papunen L; Merkin SS; Teede H; Yildiz BO
Hum Reprod; 2019 Nov; 34(11):2254-2265. PubMed ID: 31751476
[TBL] [Abstract][Full Text] [Related]
6. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
7. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
8. Polycystic Ovary Syndrome.
Azziz R
Obstet Gynecol; 2018 Aug; 132(2):321-336. PubMed ID: 29995717
[TBL] [Abstract][Full Text] [Related]
9. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
10. Is foetal hyperexposure to androgens a cause of PCOS?
Filippou P; Homburg R
Hum Reprod Update; 2017 Jul; 23(4):421-432. PubMed ID: 28531286
[TBL] [Abstract][Full Text] [Related]
11. New approach to polycystic ovary syndrome and other forms of anovulatory infertility.
Laven JS; Imani B; Eijkemans MJ; Fauser BC
Obstet Gynecol Surv; 2002 Nov; 57(11):755-67. PubMed ID: 12447098
[TBL] [Abstract][Full Text] [Related]
12. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype.
Legro RS; Chiu P; Kunselman AR; Bentley CM; Dodson WC; Dunaif A
J Clin Endocrinol Metab; 2005 May; 90(5):2571-9. PubMed ID: 15713728
[TBL] [Abstract][Full Text] [Related]
13. Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome.
Holte J
Baillieres Clin Endocrinol Metab; 1996 Apr; 10(2):221-47. PubMed ID: 8773746
[TBL] [Abstract][Full Text] [Related]
14. Adipose tissue dysfunction in polycystic ovary syndrome.
Villa J; Pratley RE
Curr Diab Rep; 2011 Jun; 11(3):179-84. PubMed ID: 21424395
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
Elkind-Hirsch KE
Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
[TBL] [Abstract][Full Text] [Related]
16. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications.
Diamanti-Kandarakis E
Expert Rev Mol Med; 2008 Jan; 10():e3. PubMed ID: 18230193
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms of Laparoscopic Ovarian Drilling and Its Therapeutic Effects in Polycystic Ovary Syndrome.
Seow KM; Chang YW; Chen KH; Juan CC; Huang CY; Lin LT; Tsui KH; Chen YJ; Lee WL; Wang PH
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142702
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
[TBL] [Abstract][Full Text] [Related]
19. Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome.
Romero-Ruiz A; Skorupskaite K; Gaytan F; Torres E; Perdices-Lopez C; Mannaerts BM; Qi S; Leon S; Manfredi-Lozano M; Lopez-Rodriguez C; Avendaño MS; Sanchez-Garrido MA; Vazquez MJ; Pinilla L; van Duin M; Kohout TA; Anderson RA; Tena-Sempere M
Hum Reprod; 2019 Dec; 34(12):2495-2512. PubMed ID: 31820802
[TBL] [Abstract][Full Text] [Related]
20. PHYSIOLOGY AND ENDOCRINOLOGY SYMPOSIUM: Insulin action and lipotoxicity in the development of polycystic ovary syndrome: A review.
Faubert J; Battista MC; Baillargeon JP
J Anim Sci; 2016 May; 94(5):1803-11. PubMed ID: 27285677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
